|
|
Avenue du Temple 19
1012 Lausanne, Switzerland
phone:+41 21 653 97 20
fax:+41 21 653 97 21
|
|
| Symbol |
Private |
| Founded |
2001 |
| Employees |
20 |
|
|
| www.symetis.com/
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Autologous Heart Valves |
|
| Management |
| Jacques R. Essinger, Ph.D., Chief Executive Officer |
| |
|
|
| |
|
| Keywords |
| biotechnology, tissue-engineered, autologous heart valves, percutaneous valve replacement (PAVR), stents |
|
|
|
| Description |
|
Symetis S.A. develops minimally invasive heart valve replacement therapies, known as transcatheter aortic valve implantation (TAVI), for patients suffering from heart valve diseases. The Company's proprietary Acurate™ Aortic Valve Replacement System features a unique self-positioning design that allows easy implant positioning and alignment within patients suffering from aortic valve stenosis, a condition characterized by a narrowing of the aortic valve opening that increases resistance to blood flow from the left ventricle to the aorta. Currently, for patients who are declined the option of surgery, physicians have little to offer besides medical therapy or balloon valvuloplasty. The Acurate TA™ Aortic Bioprosthesis and Delivery System has received CE mark certification; it includes a self-expanding nitinol stent for TAVI via transapical route, is based on a proprietary diabolo-like geometry combined with a unique reversible delivery sequence, and offers a controlled self-positioning of the valve after delivery, which makes the technology very tolerant with regard to implant positioning prior to full release. This later-stage biotechnology company also markets the Acurate TF™, a system for transfemoral delivery based on the same self-positioning concept. |
|
| Products / Services |
Symetis has designed a second-generation PAVR system that builds upon established surgical valve standards with its self-positioning stent concept (which addresses the long learning curve of earlier models).
|
|
| Market / Customers |
The heart valve replacement market is valued at $1.4 billion, and is concentrated among a small number of key players.
|
|
| Status |
| Symetis' first-in-man clinical trial of the trans-apical device planned for summer 2009. The company hopes to fund this investigation, as well as validate the trans-femoral version of its device, with approximately $12 million in financing. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members